NASDAQ:TXMDTherapeuticsMD Stock Price, Forecast & News

$1.18

+0.06 (+5.36 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.13

Now: $1.18▼

$1.23

50-Day Range

$0.87

MA: $1.16▼

$1.76

52-Week Range

$0.85

Now: $1.18▼

$4.32

Volume7.00 million shs

Average Volume4.01 million shs

Market Capitalization$320.58 million

P/E RatioN/A

Dividend YieldN/A

Beta2.1

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
TherapeuticsMD has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.67, TherapeuticsMD has a potential upside of 634.5% from its current price of $1.18.
Amount of Analyst Coverage
TherapeuticsMD has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
TherapeuticsMD has received 361 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TherapeuticsMD has received 324 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TherapeuticsMD has received 52.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote “Outperform” if you believe TXMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TherapeuticsMD does not currently pay a dividend.
Dividend Growth
TherapeuticsMD does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TherapeuticsMD insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 13.76% of the stock of TherapeuticsMD is held by insiders.
Percentage Held by Institutions
67.09% of the stock of TherapeuticsMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for TherapeuticsMD are expected to grow in the coming year, from ($0.59) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TherapeuticsMD is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TherapeuticsMD is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TherapeuticsMD has a P/B Ratio of 39.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.52 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TXMD

Previous SymbolNYSEMKT:TXMD

CUSIPN/A

CIK25743

Webwww.therapeuticsmd.com

Phone561-961-1900

Debt

Debt-to-Equity Ratio22.15

Current Ratio3.44

Quick Ratio3.20

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$49.65 million

Price / Sales6.46

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.03 per share

Price / Book39.33

Profitability

EPS (Most Recent Fiscal Year)($0.68)

Net Income$-176,150,000.00

Net Margins-333.88%

Return on Equity-1,170.63%

Return on Assets-71.17%

Miscellaneous

Employees348

Outstanding Shares271,680,000

Market Cap$320.58 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

How has TherapeuticsMD's stock been impacted by COVID-19 (Coronavirus)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD stock has decreased by 22.4% and is now trading at $1.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TherapeuticsMD.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for TherapeuticsMD.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.48 million. TherapeuticsMD had a negative return on equity of 1,170.63% and a negative net margin of 333.88%. View TherapeuticsMD's earnings history.

What guidance has TherapeuticsMD issued on next quarter's earnings?

TherapeuticsMD updated its first quarter 2020 After-Hours earnings guidance on Thursday, March, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11 million, compared to the consensus revenue estimate of $11.64 million.

What price target have analysts set for TXMD?

9 Wall Street analysts have issued 1-year price targets for TherapeuticsMD's shares. Their forecasts range from $3.00 to $15.00. On average, they anticipate TherapeuticsMD's share price to reach $8.67 in the next year. This suggests a possible upside of 634.5% from the stock's current price. View analysts' price targets for TherapeuticsMD.

Has TherapeuticsMD been receiving favorable news coverage?

Media headlines about TXMD stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutTherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

Some companies that are related to TherapeuticsMD include Odonate Therapeutics (ODT), Esperion Therapeutics (ESPR), Cytokinetics (CYTK), Aimmune Therapeutics (AIMT), I-Mab (ARQT), Phibro Animal Health (PAHC), Passage Bio (ORIC), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA), BioXcel Therapeutics (BTAI), Athenex (ATNX), Applied Therapeutics (APLT), Endo International (ENDP) and Passage Bio (IMRA). View all competitors.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), Cleveland-Cliffs (CLF), NVIDIA (NVDA), CannTrust (CNTTF), Micron Technology (MU), Horizon Therapeutics (HZNP) and Novavax (NVAX).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:

Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 49, Pay $1.22M)
Mr. John C. K. Milligan IV, Pres & Sec. (Age 58, Pay $794.68k)
Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 62, Pay $659.3k)
Mr. Mitchell L. Krassan, Exec. VP and Chief Strategy & Performance Officer (Age 54, Pay $560.53k)
Mr. Michael Donegan, VP of Fin. (Age 52, Pay $378.3k)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (7.10%), BlackRock Inc. (6.61%), Bank of New York Mellon Corp (4.67%), Franklin Resources Inc. (2.43%), C WorldWide Group Holding A S (2.28%) and State Street Corp (2.01%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View institutional ownership trends for TherapeuticsMD.

Which major investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., Two Sigma Investments LP, Morgan Stanley, Greenwood Capital Associates LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, and BlackRock Inc.. View insider buying and selling activity for TherapeuticsMD.

Which major investors are buying TherapeuticsMD stock?

TXMD stock was acquired by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Nuveen Asset Management LLC, Geode Capital Management LLC, Twin Focus Capital Partners LLC, Bay Colony Advisory Group Inc d b a Bay Colony Advisors, Raymond James & Associates, Spark Investment Management LLC, and Arizona State Retirement System. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson. View insider buying and selling activity for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $1.18.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $320.58 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 348 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is www.therapeuticsmd.com.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff